Physician profile
John M Dalena
NPI 1215944582
$7,973.55
in general payments reported to CMS, 2019-2025
28 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $714 · 2021: $903 · 2022: $948 · 2023: $1,174 · 2024: $1,392 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,241 · Education: $16.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,240.95 |
| Education | $16.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,716.62 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,166.70 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,074.26 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $807.28 | 2019-2025 | |
| Celgene Corporation | $575.61 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $516.58 | 2019-2023 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $443.88 | 2019-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $218.00 | 2023-2024 | Omvoh |
| Celltrion USA INC. | $210.71 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $175.55 | 2020-2025 | Ocaliva |
| Braintree Laboratories, INC. | $155.82 | 2019-2024 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $131.20 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $114.16 | 2019-2021 | |
| Qol Medical, LLC | $108.55 | 2021-2024 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $86.25 | 2023-2025 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $80.69 | 2021-2023 | Gimoti |
| Ardelyx, INC. | $66.74 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $64.87 | 2024-2025 | Voquezna |
| Ucb, INC. | $56.26 | 2019 | |
| Pentax of America, INC. | $44.31 | 2025 | Pentax Medical, Inspira, C2 Cryoballoon |
| Madrigal Pharmaceuticals | $41.54 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $29.74 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $17.59 | 2025 | Iqirvo |
| Genzyme Corporation | $15.63 | 2023 | |
| Redhill Biopharma INC. | $14.91 | 2021 | |
| Shire North American Group INC | $14.62 | 2019 | |
| Gilead Sciences, INC. | $14.03 | 2022 | |
| Allergan, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dalena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.